دورية أكاديمية
Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care.
| العنوان: | Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care. |
|---|---|
| المؤلفون: | Loewenthal L; National Lung and Heart Institute, Imperial College London, London, UK.; Department of Asthma and Allergy, Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, London, UK., Busby J; Centre for Public Health, Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK., McDowell R; Queen's University Belfast, Belfast, UK.; Ulster University, Coleraine, UK., Brown T; Respiratory Medicine, Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Burhan H; Respiratory Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Chaudhuri R; Respiratory Medicine, Gartnavel General Hospital, Glasgow, UK.; University of Glasgow, Glasgow, UK., Dennison P; Southampton NIHR Respiratory Biomedical Research Unit, Southampton University Hospitals NHS Trust, Southampton, UK., Dodd JW; Academic Respiratory Unit, University of Bristol, Bristol, UK.; North Bristol Lung Centre, North Bristol NHS Trust, Westbury on Trym, UK., Doe S; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK., Faruqi S; Hull University Teaching Hospitals NHS Trust, Hull, UK., Gore R; Addenbrooke's Hospital, Cambridge, UK., Idris E; Royal Stoke University Hospital, Stoke-on-Trent, UK., Jackson DJ; Guy's Severe Asthma Centre, Guy's and St Thomas' Hospitals NHS Trust, London, UK.; Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London Faculty of Life Sciences and Medicine, London, UK., Patel M; University Hospitals Plymouth, University Hospitals Plymouth NHS Trust, Plymouth, UK., Pantin T; Respiratory Medicine, Manchester University NHS Foundation Trust, Manchester, UK., Pavord I; NIHR Respiratory BRC, Nuffield Department of Medicine, Oxford University, Oxford, UK., Pfeffer PE; St Bartholomew's Hospital, London, UK., Price DB; Observational and Pragmatic Research Institute Pte Ltd, Singapore.; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK., Rupani H; University Hospital Southampton NHS Foundation Trust, Southampton, UK.; University of Southampton, Southampton, UK., Siddiqui S; National Lung and Heart Institute, Imperial College London, London, UK., Heaney LG; Centre of Infection and Immunity, Queen's University Belfast, Belfast, UK., Menzies-Gow A; Royal Brompton and Harefield Hospitals, London, UK a.menzies-gow@rbht.nhs.uk. |
| مؤلفون مشاركون: | UK Severe Asthma Registry |
| المصدر: | Thorax [Thorax] 2024 Apr 15; Vol. 79 (5), pp. 403-411. Date of Electronic Publication: 2024 Apr 15. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: British Medical Assn Country of Publication: England NLM ID: 0417353 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-3296 (Electronic) Linking ISSN: 00406376 NLM ISO Abbreviation: Thorax Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : British Medical Assn. |
| مواضيع طبية MeSH: | Asthma*/drug therapy , Asthma*/epidemiology, Humans ; Female ; Male ; Retrospective Studies ; Cross-Sectional Studies ; Biomarkers ; Obesity ; United Kingdom/epidemiology |
| مستخلص: | Introduction: After puberty, females are more likely to develop asthma and in a more severe form than males. The associations between asthma and sex are complex with multiple intrinsic and external factors. Aim: To evaluate the sex differences in the characteristics and treatment of patients with severe asthma (SA) in a real-world setting. Methods: Demographic, clinical and treatment characteristics for patients with SA in the UK Severe Asthma Registry (UKSAR) and Optimum Patient Care Research Database (OPCRD) were retrospectively analysed by sex using univariable and multivariable logistic regression analyses adjusted for year, age and hospital/practice. Results: 3679 (60.9% female) patients from UKSAR and 18 369 patients (67.9% female) from OPCRD with SA were included. Females were more likely to be symptomatic with increased Asthma Control Questionnaire-6 (UKSAR adjusted OR (aOR) 1.14, 95% CI 1.09 to 1.18) and Royal College of Physicians-3 Question scores (OPCRD aOR 1.29, 95% CI 1.13 to 1.47). However, they had a higher forced expiratory volume in 1 second per cent (FEV Conclusions: Females had increased symptoms and were more likely to be obese despite higher FEV Competing Interests: Competing interests: LL has no conflicts of interest. JB has attended advisory boards for NuvoAir, outside the submitted work. RM has no conflicts of interest. TB has received speaker fees from Astra Zeneca, Glaxo Smith Kline, Sanofi, Teva, Novartis and Chiesi; honoraria for advisory board attendance from Astra Zeneca, Sanofi and Teva; sponsorship to attend international scientific meetings from Sanofi, GSK, Teva, Chiesi and Napp Pharmaceuticals. HB has attended advisory board for AstraZeneca, GlaxoSmithKline and Sanofi; has given lectures at meetings with/without lecture honoraria supported by AstraZeneca, GlaxoSmithKline and Chiesi; has attended international conferences with AstraZeneca and Chiesi; has taken part in clinical trials sponsored by AstraZeneca, Chiesi, GlaxoSmithKline, Teva and Sanofi. RC has received lecture fees from GSK, AZ, Teva, Chiesi, Sanofi and Novartis; honoraria for Advisory Board Meetings from GSK, AZ, Teva, Chiesi, Novartis; sponsorship to attend international scientific meetings from Chiesi, Napp, Sanofi and GSK and a research grant to her Institute from AZ for a UK multicentre study. PD has received honoraria/consultancy fees/sponsorship from Teva, AZ, GSK, Novartis and Omron. JWD declares he has received honoraria for participating in advisory boards and given lectures at meetings supported by GSK, Boerhinger Ingelheim, Chiesi, AstraZeneca, Fisher & Paykel, Aerogen; he has received sponsorship for attending international scientific meetings from Chiesi; he has also taken part in asthma clinical trials sponsored by Sanofi, AstraZeneca, Chiesi for which his institution received remuneration. SD has received lecture fees from GSK, AZ, and Sanofi; honoraria for Advisory Board Meetings from GSK, AZ and Novartis; sponsorship to attend international scientific meetings from AZ, Chiesi, Sanofi and GSK. SF has received speaker fees/sponsorship to attend specialty meetings from AstraZeneca, GlaxoSmithKline, Chiesi, Novartis and Sanofi. RG has received speaking/lecture fees from GSK, AstraZeneca, Sanofi and Novartis. EI has no conflicts of interest. DJJ has received lecture fees from GSK, AZ, Teva, Chiesi, and Sanofi; honoraria for Advisory Board Meetings from GSK, AZ, Teva, Chiesi, Sanofi and Novartis; sponsorship to attend international scientific meetings from AZ, Chiesi, Napp, Sanofi and GSK and research grants to his Institute from AZ. MP has no conflicts of interest. TP has received sponsorship for attending international scientific meetings from Chiesi, GlaxoSmithKline and Sanofi Genzyme; he is also taking part in asthma clinical trials sponsored by AstraZeneca and Sanofi Genzyme for which his institution receives remuneration. IP has received speaker’s honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. PEP has attended advisory board for AstraZeneca, GlaxoSmithKline and Sanofi; has given lectures at meetings with/without lecture honoraria supported by AstraZeneca and GlaxoSmithKline; has attended international conferences with AstraZeneca; has taken part in clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Novartis and Sanofi; and is conducting research funded by GlaxoSmithKline for which his institution receives remuneration. DBP has advisory board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Viatris, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals and Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Viatris, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Viatris, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Theravance and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Viatris, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme and Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Circassia, Mundipharma, Novartis, Teva Pharmaceuticals and Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. HR has received lecture fees from GSK, AZ, Chiesi, and Sanofi; honoraria for Advisory Board Meetings from GSK, AZ and Teva; sponsorship to attend international scientific meetings from AZ and Sanofi and research grants to her Institute from GSK and AZ. SS has received honoraria for speaking or providing advisory services from AstraZeneca, Boehringer Inglehiem, GSK, CSL Behring, Chiesi, MUDIPHARMA, Owlstone Medical, ERT Medical. LGH declares he has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Circassia, Hoffmann la Roche, GlaxoSmithKline, Novartis, Theravance, Evelo Biosciences, Sanofi, and Teva; he has received grants from MedImmune, Novartis UK, Roche/Genentech, and Glaxo Smith Kline, Amgen, Genentech/Hoffman la Roche, Astra Zeneca, MedImmune, Glaxo Smith Kline, Aerocrine and Vitalograph; he has received sponsorship for attending international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; he has also taken part in asthma clinical trials sponsored by Boehringer Ingelheim, Hoffmann la Roche, and GlaxoSmithKline for which his institution received remuneration; he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with a number of pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche and Janssen. AM-G is an employee of Astra Zeneca. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.) |
| فهرسة مساهمة: | Keywords: Asthma; Asthma Epidemiology; Asthma in primary care |
| المشرفين على المادة: | 0 (Biomarkers) |
| تواريخ الأحداث: | Date Created: 20231221 Date Completed: 20240417 Latest Revision: 20240417 |
| رمز التحديث: | 20240417 |
| DOI: | 10.1136/thorax-2023-220512 |
| PMID: | 38124220 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1468-3296 |
|---|---|
| DOI: | 10.1136/thorax-2023-220512 |